drugset / Trial / NCT02156466
Multiple Ascending Dose Trial of MSB0010841 (Anti-IL17A/F Nanobody) in Psoriasis Subjects
RandomizedParallel-groupTriple-blindTreatment
Summary
This is a multicenter, Phase 1, randomized, double-blind, placebo-controlled trial in subjects with moderate to severe psoriasis to assess the safety, tolerability, immunogenicity, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of multiple subcutaneous ascending doses of MSB0010841 (Anti-interleukin-17A/F \[Anti-IL-17A/F\] Nanobody).
Timeline
- Start
- 2014-08
- Primary completion
- 2015-08
- Completion
- 2015-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | M1095 | Protein / enzyme biologic | 30 mg | Subcutaneous |
| Subject | M1095 | Protein / enzyme biologic | 60 mg | Subcutaneous |
| Subject | M1095 | Protein / enzyme biologic | 120 mg | Subcutaneous |
| Subject | M1095 | Protein / enzyme biologic | 240 mg | Subcutaneous |